Impact of Changes in Healthcare Policy, Healthcare Cost Containment and Revisions to Reimbursement Prices
First written in FY2016. 22 of 28 entries say "Restated". Latest entry: 2026-05-15.
Terumo moved to the "Worse" side of this theme in 2018, 2 years before the typical company in this theme (2020).
The whole theme swung hardest in 2025: 3 of 8 companies on the "Worse" side.
6 other companies' latest entry also says "Restated".
- 2026-05-15RestatedEarnings
「We have also estimated the impact of U.S. tariff policy and the situation in the Middle East based on certain assumptions and incorporated the estimated amounts into our earnings outlook.」
The Company incorporated the impact of tariff policy and the situation in the Middle East into the assumptions underlying its earnings forecast. - FY2025MaterialisedAnnual report
「In Japan, sales of the Neuro business and the Aortic business (formerly the Vascular business) remained strong, but sales of the Interventional Systems business declined, partly due to the impact of lower official prices, leaving overall sales up only 0.6% year on year.」
Lower official prices materialized as an actual factor behind the decline in sales of the Interventional Systems business in Japan. - FY2025-H1RestatedAnnual report
「No new business or other risks arose during the current interim consolidated accounting period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to existing business and other risks, including healthcare cost containment and drug price and official price revisions. - FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to existing business and other risks, including healthcare cost containment and drug price and official price revisions. - FY2024-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to existing business and other risks, including healthcare cost containment and drug price and official price revisions. There were no changes to the latest risk disclosures. - FY2023-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to existing business and other risks, including healthcare cost containment and drug price and official price revisions. - FY2023-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to existing business and other risks, including healthcare cost containment and drug price and official price revisions. - FY2023-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to existing business and other risks, including healthcare cost containment and drug price and official price revisions. - FY2022-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to existing business and other risks, including healthcare cost containment and drug price and official price revisions. - FY2022-Q2RestatedAnnual report
「No new business or other risks arose during the six months ended 30 September. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to existing business and other risks, including healthcare cost containment and drug price and official price revisions. - FY2022-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to the business and other risks disclosed in the previous fiscal year, including healthcare cost containment and drug price and official price revisions. - FY2021-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to existing business and other risks, including healthcare cost containment and drug price and official price revisions. - FY2021-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to the business and other risks disclosed in the previous fiscal year, including healthcare cost containment and drug price and official price revisions. - FY2020RestatedAnnual report
「In the industries in which the Company operates, institutional reforms aimed at containing healthcare costs and improving the quality of healthcare continue to be implemented in Japan and overseas.」
Changes in healthcare policy, healthcare cost containment and institutional reforms were cited as ongoing business risks, and the Company indicated that it would analyze healthcare policies in each country and respond accordingly. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to the business and other risks disclosed in the previous fiscal year, including healthcare cost containment and drug price and official price revisions. - FY2020-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The Company explained that there were no new risks or material changes to the business and other risks disclosed in the previous fiscal year, including healthcare cost containment and drug price and official price revisions. - FY2019WorsenedAnnual report
「In the third year, fiscal 2019 (the fiscal year ending March 2020), in addition to revisions to drug prices and prices of specified medical materials accompanying the scheduled October increase in Japan's consumption tax rate, and preparation costs for compliance with the newly introduced European Medical Device Regulation (MDR), higher depreciation and amortization expenses resulting from increased capital expenditure and IT investment for growth are expected.」
Regarding the risks of healthcare cost containment and reimbursement price revisions, the Company indicated that revisions to drug prices and prices of specified medical materials accompanying the consumption tax rate increase were expected to affect fiscal 2019, identifying a specific factor expected to affect the following fiscal year. - FY2019-Q3RestatedAnnual report
「In the healthcare market during the nine-month period ended 31 December 2018 (1 April 2018 to 31 December 2018), while healthcare cost containment was being pursued in various countries, drug prices and official prices were revised in Japan in April. Needs related to healthcare economics continued to increase, particularly in developed countries, to promote the focused and efficient allocation of financial resources.」
The Company continues to cite revisions to drug prices and official prices in Japan, as well as healthcare cost containment and needs related to healthcare economics in various countries, as part of the business environment. - FY2019-Q2RestatedAnnual report
「In the healthcare market during the six-month period ended 30 September 2018 (1 April 2018 to 30 September 2018), while healthcare cost containment was being pursued in various countries, drug prices and official prices were revised in Japan in April. Needs related to healthcare economics continued to increase, particularly in developed countries, to promote the focused and efficient allocation of financial resources.」
The Company continues to cite the April revisions to drug prices and official prices in Japan, as well as increasing needs for healthcare cost containment and healthcare economics. - FY2019-Q1MaterialisedAnnual report
「In the healthcare market during the three-month period ended 30 June 2018 (1 April 2018 to 30 June 2018), while healthcare cost containment was being pursued in various countries, drug prices and official prices were revised in Japan in April. Needs related to healthcare economics continued to increase, particularly in developed countries, to promote the focused and efficient allocation of financial resources.」
Drug prices and official prices were revised in Japan in April. The impact of official price revisions was also cited as a factor behind the decline in sales in Japan for the Cardiovascular company. - FY2018RestatedAnnual report
「In the second year, fiscal 2018 (the fiscal year ended March 2019), negative impacts from revisions to drug prices and prices of specified medical materials, as well as higher depreciation and amortization expenses resulting from increased capital expenditure and IT investment for growth, are expected.」
The negative impact of revisions to drug prices and prices of specified medical materials was cited as an ongoing risk in the outlook for fiscal 2018. - FY2018-Q3MaterialisedAnnual report
「In the healthcare market during the nine-month period ended 31 December 2017 (1 April 2017 to 31 December 2017), Japan decided in December on the rate of medical fee revisions for fiscal 2018, while drug prices and prices of specified medical materials were revised downward.」
The rate of medical fee revisions for fiscal 2018 was decided in December, and drug prices and prices of specified medical materials were revised downward. Specific developments related to the risks of changes in healthcare policy and reimbursement price revisions had occurred. - FY2018-Q2RestatedAnnual report
「In Japan, consideration was given to introducing cost-effectiveness assessments for pharmaceuticals and medical devices to promote the focused and efficient allocation of financial resources.」
Consideration of introducing cost-effectiveness assessments continues to be cited as part of the environment surrounding healthcare cost containment and changes in healthcare policy. No new risks or material changes to business and other risks were identified. - FY2018-Q1RestatedAnnual report
「In Japan, consideration was given to introducing cost-effectiveness assessments for pharmaceuticals and medical devices to promote the focused and efficient allocation of financial resources.」
Consideration of introducing cost-effectiveness assessments was cited as part of the environment surrounding healthcare cost containment and changes in healthcare policy. No new risks or material changes to business and other risks were identified. - FY2017-Q3RestatedAnnual report
「In Japan, drug prices and official prices were revised in April, and needs related to healthcare economics are increasing, particularly in developed countries, as cost-effectiveness assessments are being introduced on a trial basis to promote the focused and efficient allocation of financial resources.」
The trial introduction of drug price and official price revisions and cost-effectiveness assessments continues to be cited as part of the healthcare policy and healthcare cost containment environment. - FY2017-Q2RestatedAnnual report
「In Japan, drug prices and official prices were revised in April, and needs related to healthcare economics are increasing, particularly in developed countries, as cost-effectiveness assessments are being introduced on a trial basis to promote the focused and efficient allocation of financial resources.」
The trial introduction of drug price and official price revisions and cost-effectiveness assessments continues to be cited as part of the healthcare policy and healthcare cost containment environment. - FY2017-Q1MaterialisedAnnual report
「In Japan, drug prices and official prices were revised in April, and needs related to healthcare economics are increasing, particularly in developed countries, as cost-effectiveness assessments are being introduced on a trial basis to promote the focused and efficient allocation of financial resources.」
Drug prices and official prices were revised in April, and the impact of official price and drug price revisions was also cited in performance explanations by the Cardiovascular and Hospital companies. - FY2016First statedAnnual report
「In Japan, as part of measures to contain healthcare costs, revisions are made every 2 years to medical fees, drug prices and the official reimbursement prices of specified medical materials.」
Unpredictable changes in healthcare policy and official price revisions were identified as risks that could affect business performance and financial condition.